Книги по разным темам Pages:     | 1 | 2 | 3 |

plasa hoocyst (e) ine should be treated Effects of vitain Hyperhoocysteineia but not the C677 T utation of MTHFR therapy on progression of carotid atherosclerosis in patients is an independent risk deterinant of carotid wall thickening // with hoocyst (e) ine levels above and below 14 icrool L // Circulation. 1999. Vol. 99. P. 2383Ц2388.

Aer. J. Hypertens. 2000. Vol. 13. P. 105Ц110.

13. Li H. Hoocysteine induces 3-hydroxy-3-ethilglutaril 37. Konings E. J. Dietary folates in huan nutrition: thesis coenzye a reductase in vascular endothelial cells: A echanis University of Maastricht, The Neterlands, 2001. P. 105Ц120.

for developent of atherosclerosis // Circulation. 2002. Vol. 105.

38. The increase of plasa hoocysteine concentrations P.1037Ц1042.

with age is partly due to the deterioration of renal function as 14. Hoocysteine induces 3-hydroxy-3-ethylglutaryl deterined by plasa cystatin / L. Norlund, A. Grubb, G. Fex [et coenzye A reductase in vascular endothelial cells / Н. Li, А. Lewis, al.] // Lab. Med. 1998. Vol. 36. P. 175Ц178.

S. Brodsky [et al.] // Circulation, 2002 Vol. 105. P. 1037Ц1043.

39. Coffee consuption and plasa total hoocysteine:

15. Plasa hoocysteine concentretion, statin therapy, the Hordaland Hoocysteine study / O. Nygard, H. Refsu, and the risk of first acute coronary eventsker / P. M. Rid, J. Shih, P. M. Ueland [et al.] // A. J. Clin. Nutr. 1997. Vol. 65. P. 136ЦT. J. Cook [et al.] // Circulation. 2002. Vol. 105. P. 1776Ц1779.

40. Refsu H., Ueland P. M. Clinical significance of 16. Lang D., Kredan M. B., Lang D., Moat S. J. Hoocysteine Ч pharacological odulation of hoocysteine etabolis // induced inhibition of endotheliu-dependent relaxation in rabbit Trends Pharacol Sci. 1990. Vol. 11. P. 411Ц416.

aorta Role for superoxide anions // Arterioscler. Throb. Vasc.

41. Schneede J., Refsu H., Ueland P. M. Biological and Biol. 2000. P. 367Ц373.

environental deterinants of plasa hoocysteine // Sein.

17. Uel P. M., Refsu H. Plasa hoocysteine, a risk factor Throb. Heost. 2000. Vol. 26. P. 263Ц279.

for vascular disease plasa levels in health, disease, and drug 42. Decreased rate of coronary restenosis after lowering of therapy // Мed. 1989. Р. 114Ц501.

plasa hoocysteine levels / G. Schnyder, M. Roffi, R. Pin [et al.] 18. The effect of horone replaceent therapy on seru //N. Engl. J. Med. 2001. Vol. 345. P. 1593Ц1600.

hoocysteine levels in perienopausal woen: a randoized 43. Elevated plasa concentrations of hoo-cysteine controlled study / E. Hak, A. Bak, J. Lindeans [et al.] // in antiepileptic drug treatent / M. Schwaninger, P. Ringleb, Atherosclerosis, 2001. Vol. 158. P. 437Ц439.

R. Winter // Epilepsia.1999. Vol. 40. P. 345Ц350.

19. Hansrani M. Hoocysteine in yointial hyperplasia // 44. The effect of a subnoral vitain B-6 status on Vasc Endovasc Surg. 2002. Vol. 23. P. 3Ц10.

hoocysteine etabolis / J. B. Ubbink, R. Delport, R. H. Allen 20. Harker L., Ross R., Slichter S., Scott C. Hoocysteineia:

[et al.] // J. Clin. Investig. 1996. Vol. 98. P.177Ц184.

vascular injury and arterial throbosis // N. Engl. J. Med. 1974.

45. Ueland P. M., Refsu H. Plasa hoocysteine, a risk Vol. 291. P. 537Ц543.

factor for vascular disease: plasa levels in health, disease and 21. Loscalo J. The oxidant stress of hyperhoocyst (e) drug therapy // J. Lab. Clin. Med. 1989. Vol. 114. P. 473Цineia // J. Clin. Invest. 1996 Vol. 98. P. 5Ц7.

46. 5-ethyltetrahydrofolate, the active for of folic acid, 22. Wotherspoon F., Laight D., Shaw K., Curestores endothelial function in failial hypercholesteroleia / ings M. Hoocysteine, endothelial dysfunction and oxidative M. C. Verhaar, R. M. Wever, J. J. Kastelein [et al.] // Circulation.

stress in type 1 diabetes ellitus // Br. J. Diabetes Vasc. Dis.

1998. Vol. 97. P. 237Ц241.

2003. Vol. 3. P. 334Ц340.

47. Effects of oral folic acid suppleentation on endothelial 23. Баранова Е. И., Большакова О. О. Клиническое знаfunction in failial hypercholesteroleia: A randoized чение гомоцистеинемии (обзор литературы) // Артериальная placeboFcontrolled trial / M. C. Verhaar, R. M. Wever, гипертензия. 2004. № 10. C. 85Ц87.

J. J. Kastelein [et al.] // Circulation. 1999. Vol. 100. P. 335Ц338.

24. Баркаган З. С. Учение о тромбофилиях на современ48. Norohoocysteinaeia and vitainFtreated ном этапе // Консилиум. 2000. № 6. C. 61Ц65.

hyperhoocysteinaeia are associated with siilar risks of 25. Баркаган З. С., Костюченко Г. И., Котовщикова Е. Ф. Гиcardiovascular events in patients with preature atherothrobotic пергомоцистеинемия как самостоятельный фактор риска поcerebrovascular disease / E. G. Vereulen, J. A. Rauwerda, ражения и тромбирования кровеносных сосудов // Патология P. Erix [et al.] // A prospective cohort study. Neth. J. Med. 2000.

кровообращения и кардиохирургия / 2002. № 1. C. 65Ц71.

Vol. 56. P. 138Ц146.

26. Ефимов В. С., Цакалов А. К. Гомоцистеинемия в патогенезе тромбоваскулярной болезни и атеросклероза // Лаб.

References мед. 1999. № 2. C. 44Ц48.

27. Лысенко М. Э. Коррекция гипергомоцистеинемии у 1. McCully K. S. Vascular pathology of hoocysteineia:

больных ИБС // Украинский терапевтический журнал. 2004. iplications for the pathogenesis of atherosclerosis // № 1. C. 69Ц73. Aer. J. Pathol. 1969. Vol. 56. P. 111Ц128.

Saratov Journal of Medical Scientific Research. 2011. Vol. 7, № 3.

624 ВНУТРЕННИЕ БОЛЕЗНИ 2. Stapfer M. Can lowering hoocysteine levels reduce 27. Lysenko M.Je. Korrekcija gipergoocisteineii u bolТnyh cardiovascular risk // Engl. J. Med. 1995. Р. 328Ц332. IBS // Ukrainskij terapevticheskij zhurnal. 2004. № 1. C. 69Ц73.

3. Mayer E., Jacobsen D., Robinson К. Hoocysteine and 28. Muhin N.A., Moiseev S.V., Foin V.V.

coronary atherosclerosis // J. A Coll Cardiol.. 1996. Р. 517Ц527.

Gipergoocisteineija kak faktor riska razvitija zabolevanij 4. Hankey G. J. Hoocysteine and vascular disease // serdechno-sosudistoj sistey // Klinicheskaja edicina. 2001.

Lancet. 1999. Vol. 354. P. 407Ц413.

№ 6. s. 7Ц5. MacMahon M., Kirkpatrick C. Nutr Metab Cardiovasc // 29. Shevchenko O.P., Olefrienko G.A. Gipergoocisteineija Dis. 2000. Vol. 10. Р 195Ц203.

i ee klinicheskoe znachenie // Laboratorija. 2002. № 1. C. 3Ц7.

6. Hoocysteine and short Ч ter risk of yocardial infarction 30. Sheleva V.M. Gipergoocisteineija i troboz // and stroke in the elderly / М. Bots, L. Launer, J. Lindeans [et al.] Troboz, geostaz i reologija. 2000. № 4. C. 26Ц29.

// The Rotterda Study Arch. Intern. Med. 1999. Р. 138Ц159.

31. Hubutija M.Sh., Shevchenko O.P. Goocistein pri 7. Bonitton-Kopp. С. Early carotid atherosclerosis in healthy koronarnoj bolezni serdca i serdechnogo transplantanta. M.:

iddle-aged woen // Kopp. Ibid, 1993. Vol. 24. P 1837Ц1843.

Refar, 2004. 272 s. 32. Arnadottir M. Hoocysteine in renal 8. Single LDL apheresis iproves endotheliu Ч dependent disease, in Hoocysteine in health and disease // Cabridge vasodilatation in hypercholesteroleic huans / O. Taai, University Press, Cabridge, UK, 2001. P. 321Ц330.

H. Matsuoka, H. Itabe [et al.] // Circulation. 1997. Vol. 95. P. 76Ц82.

33. Plasa hoocysteine in woen on oral oestrogen9. For the West of Scotland Coronary Prevention Study Group containing contraceptives and in en with oestrogen-treated Prevention of coronary heart disease with pravastatin in en with prostatic carcinoa / L. Brattstro, B. Israelsson, A. Olsson [et hypercholesteroleia / J. Shepherd, S. M. Cobbe, I. Ford [et al.] // al.] // Scand. J. Clin. Lab. Investig. 2001. Vol. 52. P. 283ЦN. Engl. J. Med. 1995. Vol. 333. P. 1301Ц1307.

34. Lowering blood hoocysteine with folic acid based 10. Engl N. The Long-Ter Intervention with Pravastatin suppleents: eta-analysis of randoised trials / L. Brattstro, in Ischaeic Disease (LIPID) Study Group. Prevention of F. Landgren, B. Israelsson [et al.] // Br. Med. J. 1998. Vol. 316.

cardiovascular events and death with Pravastatin in patients with P. 894Ц898.

coronary heart disease and a broad range of initial cholesterol levels // J. Med. 1998. Vol. 339. P. 1349Ц1357. 35. Unfiltered coffee increases plasa hoocysteine 11. Effect of pravastatin on endothelial function in patients with concentrations in healthy volunteers: a randoized coronary artery disease / A. Masuoto, Y. Hirooka, K. Hironaga trial / M. J. Grubben, G. H. Boers, H. J. Blo [et al.] // A. J. Clin.

[et al.] // Aer. J. Cardiol, 2001. Vol. 88. P. 1291Ц1294.

Nutr. 2000. Vol. 71. P. 480Ц484.

12. McQuillan B. M., Beilby J. P., Nidorf P. L. Thopson.

36. Hacka D. G., Peterson J. C., Spence J. D. What level of Hyperhoocysteineia but not the C677 T utation of MTHFR plasa hoocyst (e) ine should be treated Effects of vitain is an independent risk deterinant of carotid wall thickening // therapy on progression of carotid atherosclerosis in patients Circulation. 1999. Vol. 99. P. 2383Ц2388.

with hoocyst (e) ine levels above and below 14 icrool L // 13. Li H. Hoocysteine induces 3-hydroxy-3-ethilglutaril Aer. J. Hypertens. 2000. Vol. 13. P. 105Ц110.

coenzye a reductase in vascular endothelial cells: A echanis 37. Konings E. J. Dietary folates in huan nutrition: thesis for developent of atherosclerosis // Circulation. 2002. Vol. 105.

University of Maastricht, The Neterlands, 2001. P. 105Ц120.

P.1037Ц1042.

38. The increase of plasa hoocysteine concentrations 14. Hoocysteine induces 3-hydroxy-3-ethylglutaryl with age is partly due to the deterioration of renal function as coenzye A reductase in vascular endothelial cells / Н. Li, А. Lewis, deterined by plasa cystatin / L. Norlund, A. Grubb, G. Fex [et S. Brodsky [et al.] // Circulation, 2002 Vol. 105. P. 1037Ц1043.

al.] // Lab. Med. 1998. Vol. 36. P. 175Ц178.

15. Plasa hoocysteine concentretion, statin therapy, 39. Coffee consuption and plasa total hoocysteine:

and the risk of first acute coronary eventsker / P. M. Rid, J. Shih, the Hordaland Hoocysteine study / O. Nygard, H. Refsu, T. J. Cook [et al.] // Circulation. 2002. Vol. 105. P. 1776Ц1779.

P. M. Ueland [et al.] // A. J. Clin. Nutr. 1997. Vol. 65. P. 136Ц16. Lang D., Kredan M. B., Lang D., Moat S. J. Hoocysteine Ч 40. Refsu H., Ueland P. M. Clinical significance of induced inhibition of endotheliu-dependent relaxation in rabbit pharacological odulation of hoocysteine etabolis // aorta Role for superoxide anions // Arterioscler. Throb. Vasc.

Trends Pharacol Sci. 1990. Vol. 11. P. 411Ц416.

Biol. 2000. P. 367Ц373.

41. Schneede J., Refsu H., Ueland P. M. Biological and 17. Uel P. M., Refsu H. Plasa hoocysteine, a risk factor environental deterinants of plasa hoocysteine // Sein.

for vascular disease plasa levels in health, disease, and drug Throb. Heost. 2000. Vol. 26. P. 263Ц279.

therapy // Мed. 1989. Р. 114Ц501.

18. The effect of horone replaceent therapy on seru 42. Decreased rate of coronary restenosis after lowering of hoocysteine levels in perienopausal woen: a randoized plasa hoocysteine levels / G. Schnyder, M. Roffi, R. Pin [et al.] controlled study / E. Hak, A. Bak, J. Lindeans [et al.] // //N. Engl. J. Med. 2001. Vol. 345. P. 1593Ц1600.

Atherosclerosis, 2001. Vol. 158. P. 437Ц439.

43. Elevated plasa concentrations of hoo-cysteine 19. Hansrani M. Hoocysteine in yointial hyperplasia // in antiepileptic drug treatent / M. Schwaninger, P. Ringleb, Vasc Endovasc Surg. 2002. Vol. 23. P. 3Ц10.

R. Winter // Epilepsia.1999. Vol. 40. P. 345Ц350.

20. Harker L., Ross R., Slichter S., Scott C. Hoocysteineia:

44. The effect of a subnoral vitain B-6 status on vascular injury and arterial throbosis // N. Engl. J. Med. 1974.

hoocysteine etabolis / J. B. Ubbink, R. Delport, R. H. Allen Vol. 291. P. 537Ц543.

[et al.] // J. Clin. Investig. 1996. Vol. 98. P.177Ц184.

21. Loscalo J. The oxidant stress of hyperhoocyst (e) 45. Ueland P. M., Refsu H. Plasa hoocysteine, a risk ineia // J. Clin. Invest. 1996 Vol. 98. P. 5Ц7.

factor for vascular disease: plasa levels in health, disease and 22. Wotherspoon F., Laight D., Shaw K., drug therapy // J. Lab. Clin. Med. 1989. Vol. 114. P. 473ЦCuings M. Hoocysteine, endothelial dysfunction and 46. 5-ethyltetrahydrofolate, the active for of folic acid, oxidative stress in type 1 diabetes ellitus // Br. J. Diabetes Vasc.

restores endothelial function in failial hypercholesteroleia / Dis. 2003. Vol. 3. P. 334Ц340.

M. C. Verhaar, R. M. Wever, J. J. Kastelein [et al.] // Circulation.

23. Baranova E.I., BolТshakova O.O. Klinicheskoe znachenie 1998. Vol. 97. P. 237Ц241.

goocisteineii (obzor literatury) // ArterialТnaja gipertenzija.

47. Effects of oral folic acid suppleentation on endothelial 2004. № 10. C. 85Ц87.

function in failial hypercholesteroleia: A randoized 24. Barkagan Z.S. Uchenie o trobofilijah na sovreenno placeboFcontrolled trial / M. C. Verhaar, R. M. Wever, J. J. Kastejetape // Konsiliu. 2000. № 6. C. 61Ц65.

lein [et al.] // Circulation. 1999. Vol. 100. P. 335Ц338.

25. Barkagan Z.S., Kostjuchenko G.I., Kotovwikova E.F.

48. Norohoocysteinaeia and vitainFtreated hyperhoGipergoocisteineija kak saostojatelТnyj faktor riska ocysteinaeia are associated with siilar risks of cardiovasporazhenija i trobirovanija krovenosnyh sosudov // Patologija cular events in patients with preature atherothrobotic cerekrovoobrawenija i kardiohirurgija / 2002. № 1. C. 65Ц71.

brovascular disease / E. G. Vereulen, J. A. Rauwerda, P. Erix 26. Cakalov A.K., Efiov V.S. Goocisteineija v patogeneze trobovaskuljarnoj bolezni i ateroskleroza // Lab. [et al.] // A prospective cohort study. Neth. J. Med. 2000. Vol. 56.

ed. 1999. № 2. C. 44Ц48. P. 138Ц146.

Саратовский научно-медицинский журнал. 2011. Т. 7, № 3.

Pages:     | 1 | 2 | 3 |    Книги по разным темам